Market Overview

UPDATE: Tigress Initiates Coverage On Illumina

Related ILMN
Benzinga's Volume Movers
Morning Market Gainers

In a report released Friday, Tigress analyst Philip Van Deusen initiated coverage on Illumina (NASDAQ: ILMN) with a Buy rating.

Analysts at Tigress favor Illumina for reducing costs in its genomic health progress with its genetic testing, diagnosis and individualized treatment. Illumina's development of hardware will strengthen, influencing an increase to barriers to entry. Tigress holds high expectations for Illumina sequencing machines, growing 51 percent year over year and making a majority of the company's revenue.

Latest Ratings for ILMN

Oct 2015Piper JaffrayMaintainsOverweight
Oct 2015BarclaysMaintainsEqual-weight
Oct 2015Mizuho SecuritiesDowngradesBuyNeutral

View More Analyst Ratings for ILMN
View the Latest Analyst Ratings

Posted-In: Philip Van Deusen TigressInitiation Analyst Ratings


Related Articles (ILMN)

View Comments and Join the Discussion!

Get Benzinga's Newsletters